HER2+ Breast Cancer

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

The HER2-directed ADC FS-1502 was well tolerated and generated early signals of antitumor activity in patients with HER2-expressing breast cancer.

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

Peter Forsyth, MD, discusses a study of intrathecal dendritic cells in patients with leptomeningeal disease from TNBC or HER2-positive breast cancer.

Long-term outcomes with subcutaneous pertuzumab/trastuzumab plus chemo were comparable to the IV combo in HER2+ early breast cancer.

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Julia Foldi, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment paradigm for metastatic HER2-positive breast cancer.

Adding atezolizumab to neoadjuvant pertuzumab, trastuzumab, and chemotherapy produced improved EFS and DFS rates in HER2-positive early breast cancer.

Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.

Shruti Tiwari, MD, discusses how the treatment paradigms for HER2-positive and HER2-low breast cancer has evolved in recent years.

A real-world study dives into treatment sequencing data and indicates most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in the US.

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.